Albenatide vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Albenatide
Developed by ConjuChem and partners
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Number and percentage of treatment emergent adverse events (TEAE) and serious adverse events (SAE)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Albenatide | XW014 |
|---|---|---|
| HbA1c, change | -0.8% vs -0.5%−0.4 vs placeboNCT006387161 other result
| —Not reported |
| Body weight, change (kg) | -2.0 vs -1.6−0.4 vs placeboNCT006387161 other result
| —Not reported |
| HbA1c below 7% | —Not posted · NCT07058545 | —Not reported |
| Fasting plasma glucose, change | -0.8 vs -0.6−0.2 vs placeboNCT006387161 other result
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT07058545 | —Not reported |
HbA1c, change
- Albenatide
- -0.8% vs -0.5%−0.4 vs placeboNCT00638716
1 other result
- -1.3% vs -0.3% NCT00674466
- XW014
- —Not reported
Body weight, change (kg)
- Albenatide
- -2.0 vs -1.6−0.4 vs placeboNCT00638716
1 other result
- -1.2 vs -0.4 NCT00674466
- XW014
- —Not reported
HbA1c below 7%
- Albenatide
- —Not posted · NCT07058545
- XW014
- —Not reported
Fasting plasma glucose, change
- Albenatide
- -0.8 vs -0.6−0.2 vs placeboNCT00638716
1 other result
- -0.3 vs 0.7 NCT00674466
- XW014
- —Not reported
3-point MACE (% with event)
- Albenatide
- —Not posted · NCT07058545
- XW014
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
XW014: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Albenatide: 3 of 4 rows · XW014: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Albenatide |
|---|---|
| Dropout rate | 14%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result23.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result—1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result3.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1.5 mga nausea 22.4% (placebo 15.8%) diarrhea 12.2% (placebo 5.3%) vomiting 12.2% (placebo 3.5%) NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result1.5 mg headache 26.7% (placebo 24.1%) nausea 26.7% (placebo 13.8%) vomiting 23.3% (placebo 17.2%) NCT00674466 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Albenatide
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · XW014's landscape